B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target
MacroGenics (MGNX) has an average rating of buy and price targets ranging from $16 to $30, according to analysts polled by Capital IQ.
Daily rights tracking | Big investors are bullish on Meta against the market! Spending $144 million to buy Call
Tesla rose nearly 5% overnight. 2.92 million options were traded, and the bullish ratio rose to 46.9%. A single call with an exercise price of $167.5/170, which expires today, earns more than 3 times the premium.
Buy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial Results
We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely
Companies Like MacroGenics (NASDAQ:MGNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, MacroGenics (NASDAQ:MGNX) has seen its share price rise 157% over the last year, delighting ma
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Buy Rating Affirmed for MacroGenics With Promising Vobra Duo Data and Anticipated 2024 Clarifications
Macrogenics Raised to Buy From Hold by TD Cowen
Macrogenics Raised to Buy From Hold by TD Cowen
TD Cowen: Upgraded the Macrogenics (MGNX.US) rating from holding to buying.
TD Cowen: Upgraded the Macrogenics (MGNX.US) rating from holding to buying.
TD Cowen Upgrades Macrogenics to Buy
TD Cowen analyst Boris Peaker upgrades Macrogenics from Hold to Buy.
Macrogenics(MGNX.US) Officer Sells US$799.15K in Common Stock
$Macrogenics(MGNX.US)$ Officer Peters Jeffrey Stuart sold 51,395 shares of common stock on Apr 4, 2024 at an average price of $15.55 for a total value of $799.15K.Source: Announcement What is statemen
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with
Form 144 | Macrogenics(MGNX.US) Officer Proposes to Sell 798.79K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Macrogenics(MGNX.US)$ Officer Peters Jeffrey Stuart intends to sell 51,395 shares of its common stock on Apr 4, with a total market value of approximately $798.79K. P
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
Wednesday, MacroGenics Inc (NASDAQ:MGNX) provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) for metastatic castration-resistant prost
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%
BRNS, UPC and KWE Among Mid-day Movers
MacroGenics Shares Surge Following Phase 2 Update on Prostate Cancer Drug
MacroGenics (MGNX) shares jumped 33% in recent trading Thursday, a day after the company said it will present updated clinical information in autumn on radiographic progression-free survival from the
MacroGenics Up Nearly 32%, on Pace for Largest Percent Increase Since May 2020 -- Data Talk
MacroGenics, Inc. (MGNX) is currently at $18.00, up $4.34 or 31.71% --Would be highest close since March 7, 2024, when it closed at $20.51 --On pace for largest percent increase since May 6, 2020, w
JMP Securities Reiterates Market Outperform on Macrogenics
JMP Securities analyst Silvan Tuerkcan reiterates Macrogenics with a Market Outperform.
No Data